Background: Diabetes and its complications constitute a rising medical chal-
most prevalent cause of morbidity and death in patients with diabetes is cardiovascular disease. Amongst all complications, special attention should be given to diabetic foot syndrome (DFS).
Diabetic foot is defined as infection, ulceration or destruction of deep tissues of the foot that is associated with neuropathy and/or periphery arterial disease in the lower extremity of patients with diabetes mellitus. 5 Based on this definition, it becomes apparent that the pathomechanism of DFS is complex, involving elements of diabetic neuropathy and local ischaemia. Despite new therapeutic advances, many patients still develop various forms of DFS at different stages. DFS is associated with a high rate of amputation and excessive mortality. 6 It was estimated that every minute, two lower limbs or parts of a lower limb are lost somewhere in the world as a consequence of DFS. 7 Diabetic foot ulceration (DFU) is a frequently diagnosed variant of DFS. The annual incidence rate reported worldwide amongst persons with diabetes exceeds 6.0%. 8 The IDF remarked that foot ulcers develop in up to 26.1 million diabetic patients around the globe annually. 9 Of note, foot ulcers precede more than 85% of nontraumatic lower extremity amputations in subjects with diabetes. 10 On the positive side, medical, organizational and financial investments in diabetic foot ulcer care might improve this alarming statistic.
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2 | THE CONCEPT OF NEGATIVE
PRESSURE WOUND THERAPY
It is widely accepted around the world that standard therapy of DFU should include glycemic control, offloading of weight and pressure, revascularization, systemic antibiotics, surgical debridement and different topical applications. 13 Nevertheless, in many patients, this standard therapy is not sufficient as they experience prolonged healing and the rate of recurrence of ulceration after the initial closure is high. 14 Thus, there is an real need for additional therapies that could improve prognosis in patients with DFU. Negative pressure wound therapy (NPWT) is one of the most frequently used adjunct approaches in patients with DFU. The first report on its possible therapeutic usefulness came more than two decades ago. A group of scientists involved in plastic and reconstructive surgery research initially reported that subatmospheric pressure technique accelerated wound healing in a pig animal model. 15 The application of such controlled subatmospheric pressure resulted in increased local blood flow and tissue formation, as well as decreased tissue bacterial counts. Since then, there have been hundreds of experimental and clinical papers on NPWT, including its use in a number of conditions in humans. This list involves acute, chronic and postsurgical wounds, including those localized in the abdomen and sternum, open fractures, foot pressure ulcers (particularly in diabetes), grafts and flaps. 16 Negative pressure wound therapy is a general term that includes all devices firmly sealing the wound and creating a near airtight setting to which a vacuum is connected. This term is sometimes used interchangeably with another name, vacuum-assisted closure (VAC). 17 VAC has a narrower meaning, as it refers to the most common commercially available system using NPWT (KCI, San Antonio, Texas). An essential component of any NPWT device is a porous material, such as foam or gauze, filling the wound and facilitating pressure transmission. A dressing consisting of an occlusive drape, traversed by a drainage tube, is then applied to the wound opening, forming a seal under which a negative pressure is present. The drainage tube is connected to a negative pressure unit that generates negative pressure, typically between −50 and −150 mm Hg. 17, 18 Different modes of NPWT are used-continuous, intermittent or variable-the first one being the most commonly applied. The specific interface material that contacts the wound surface affects the biological response of the system. The most commonly used material is a reticulated open-pore polyurethane foam. It forms a structure resembling a three-dimensional net. This construction allows the negative pressure to be evenly distributed throughout the foam and improves the biological effects of the system. Table 1 summarizes different types and modes of NPWT systems as well as the most important areas of clinical applications.
Below we summarize the current knowledge concerning the tissue, cellular and molecular mechanisms of NPWT action with particular emphasis on evidence emerging from diabetes-related research. This is followed by a summary of clinical NPWT studies, both randomized and observational, involving patients with diabetes and DFU, as well as the place of this modality in current diabetic practice guidelines.
| TISSUE AND CELLULAR LEVEL OF NPWT ACTION
Negative pressure wound therapy action results in two types of tissue deformations: macrodeformation (ie, wound contraction) and microdeformation that occurs at microscopic level. Both of them are thought to influence mostly early stages of wound healing, that is inflammatory and proliferative phases. 15, [19] [20] [21] [22] [23] The beneficial effect of NPWT in terms of wound contraction has been shown in many animal and human studies, including those involving patients with DFS. [24] [25] [26] By generating subatmospheric pressure across the entire wound bed, NPWT systems draw wound margins together. The NPWT effect on wound contraction depends on tension on wound edges and skin elasticity. 18 As a result of this fact, in patients with DFS, the post-surgical wounds are expected to be more effectively contracted after NPWT application, as illustrated by Figure 1 , than nonsurgical ones. A polyurethane or polyvinyl foam, as well as gauze, are used as a wound filler with different predicted benefits and disadvantages. [27] [28] [29] However, in vivo porcine model studies revealed no differences in wound area reduction when using gauze or foam 24, 30 and no randomized studies on wound filler of NPWT in subjects with DFS were performed. In animal models, the macrodeformation degree was also not associated with the level of negative pressure delivered by NPWT systems. 24 This is in line with the results of a randomized clinical trial in which a high negative pressure level (−l25 mm Hg) with polyurethane foam was compared with a low pressure (−75 mm Hg) with a silicone-coated dressing for the treatment of DFUs. 31 Microdeformation is an effect of NPWT at a cellular level. The tissue surface is estimated to be strained in 5%-20% by NPWT 32 ; moreover, negative pressure applied on the wound bed results in an undulated wound surface and a presence of tissue blebs pulled into the pores of the dressing. 24 This mechanical stress transferred to the cells induces activation of a healing cascade, including cell proliferation, migration and differentiation, granulation tissue promotion, angiogenesis and epithelialization. [32] [33] [34] It was shown in several studies that NPWT changes local blood flow and reduces local oedema by generating subatmospheric pressure. The change in local blood flow after NPWT depends on the degree of negative pressure provided and the type of foam used. [35] [36] [37] [38] Hyperperfusion close to the wound edge is thought to be beneficial through oxygenation and nutrient supply improvement, while hypoperfusion in the wound edge is thought to aid through angiogenesis stimulation. Local oedema reduction results from excess extracellular fluid removal and leads to decreased hydrostatic compression at the capillaries and reduction in the required diffusion distance. 18 Interestingly, rapid significant periwound tissue oedema reduction was observed after just a few days of therapy in patients with different wound types. 39, 40 By extracting excess wound fluid, NPWT removes inflammatory cytokines and proteases that may worsen healing processes. 33, 41 Moreover, as NPWT extracts wound exudates, it also helps to maintain clean moist wound environments and leads to less frequent dressing changes. Additionally, there are also some data on bacterial load reduction as a result of NPWT use. 15, 42 For example, it has been recently shown that in patients with different wounds characteristics, bacterial load, including the magnitude of different bacteria and their amount, was decreased after NPWT treatment. 43 However, in earlier prospective randomized trials, a significant wound area reduction was seen in the NPWT group, but was not associated with bacterial load reduction. 44, 45 Interestingly, preliminary data from a prospective study in patients with a broad spectrum of wounds show that NPWT might modulate antibiotic concentrations in wounds. 46 NPWT is suspected to increase antibiotic concentration by promoting their delivery through removal of excess exudates, blood flow improvement and promotion of highly vascularized tissue granulation. 46 Further studies are, however, needed to confirm these mechanisms.
| NEGATIVE PRESSURE WOUND THERAPY MOLECULAR MECHANISMS
The question regarding the potential molecular mechanisms through which NPWT promotes angiogenesis and granulation has been asked since its very introduction to clinical practice. It was postulated that hypoxia and stress generated locally by NPWT might influence gene expression. This hypothesis was investigated in several types of studies, including in vitro and in vivo subtypes, the latter involving either animal models or human studies. 47 Most reports have come from nondiabetic settings and models. A variety of methods were used to assess the local expression within the wound bed of genes or proteins, as well as circulating levels of biomarkers that seemed crucial for the processes of angiogenesis and granulation. The list includes quantitative reverse transcription (RT)-PCR, enzyme-linked immunosorbent assay (ELISA), immunochemistry techniques, DNA microarray technology and some others. Almost all studies focused selectively on pathways previously identified to be involved in the wound healing processes, while very few used a global approach with an initial null hypothesis. In keeping with the postulated crucial role of mechanisms related to processes of neovascularization and granulation, most of the research has focused on two groups of genes-growth factors and cytokines. In general, NPWT has been proven to result in an alteration towards more pro-angiogenic and anti-inflammatory molecular conditions. Specifically, in response to conditions generated by negative pressure, expression of several key growth factors, such as vascular endothelial growth factor (VEGF), transforming growth factor (TGF) beta, fibroblast growth factor (FGF) 2 and platelet-derived growth factor (PDGF), was increased. [47] [48] [49] On the other hand, expression of tumour necrosis factor (TNF)-α, a cytokine involved in systemic inflammation, was reduced in acute and chronic wounds, whereas expression of interleukin (IL) 1β, another important mediator of inflammatory responses, was reduced in acute wounds only. 41, 47, 50 Expression of systemic IL-10, an anti-inflammatory cytokine, and local IL-8, a potent chemokine and pro-angiogenic factor, was increased by NPWT. 20, 51 Other groups of particles that were examined in the context of NPWT action are matrix metalloproteinases (MMPs). They are collagenases, gelatinases and stromelysins that not only remodel the extracellular matrix (ECM), but are also involved in inflammatory and cutaneous wound healing processes.
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A few available studies reported that expression of some MPPs, notably MMP-1, MMP-2, MMP-9 and MMP-13, was reduced after application of NPTW.
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Chronic excess of glucose affects expression of many genes and impairs wound healing through a variety of mechanisms, such as a fibroblasts dysfunction, decreased production of ECM proteins, nitric oxide deficiency, abnormal function of MMPs, as well as several others. 55 Thus, results from nondiabetic models of NPWT molecular action cannot be automatically extrapolated to diabetic environments. The recent study performed in patients with type 2 diabetes, however, seems to confirm earlier nondiabetic data. 56 Based on granulation tissue biopsies before and after NPWT, it was concluded that mRNA levels of IL-1β, TNF-α, MMP-1 and MMP-9 were significantly downregulated, while the levels of VEGF, TGF-β1 and TIMP-1 were significantly increased. There were three other small studies from a Chinese population that either pointed to several genes already mentioned in this review (TGF-β1, bFGF) or reported some others (eg, cFN-cellular fibronectin, an important ECM protein). Thus, in humans with diabetes, three already discussed groups of genes-growth factors, inflammatory cytokines and MMPs -seemed to constitute molecular mechanisms affected by vacuum therapy. Generally, data from humans find its confirmation in an animal model study performed a decade ago. In this study, a whole genome microarray method was used to identify the biological pathways altered during the healing processes in acute excisional wounds in Zucker diabetic rats treated with NPWT, moist wound healing or gauze under suction. 57 The analyses of expression 58 Interestingly, all four genes seemed to be functionally involved in wound healing by influencing re-epithelialization and angiogenesis. They were not reported earlier as genes potentially related to NPWT action. It is, however, important to note that some differences between the study results are not surprising as they were characterized by a variety of wound models (in vitro and in vivo, human and animal), species, type of wound (acute, chronic or surgical), sample size, magnitude and duration of NPWT, timepoints of treatment application, control intervention, method of analysis and quantitative end-points. Nevertheless, they not only provide insight into the molecular mechanisms of NPWT action, but also may help in its clinical application and the development of new therapies. A schematic summary of putative molecular mechanisms is summarized in Figure 2 .
| NEGATIVE PRESSURE WOUND THERAPY CLINICAL HUMAN STUDIES AND ITS PLACE IN MEDICAL GUIDELINES
The place of all drugs and medical technologies in contemporary clinical guidelines is determined mainly by scientific evidence procured by randomized controlled trials (RCTs) and their meta-analyses, as well as real-world evidence. There were two meta-analyses of RCTs published in recent years involving NPWT in patients with DFUs including 8 and 11 studies, respectively. 59, 60 Although these studies included patients with both type 1 and type 2 diabetes, the individuals with the latter form of disease seemed to constitute altogether 90% of the examined individuals. While most patients suffered from chronic foot ulcers, there were also ones with post-operative wounds. The wounds were variable in terms of size, specific foot location and grade of severity. Different types of NPWT technologies were used, from commercially available devices to "home-made" systems. Whereas most studies used a continuous negative pressure algorithm, they differed substantially in terms of time of NPWT application -from two weeks up to almost four months. Standard DFS care was used as the comparison. The typical efficacy outcomes evaluated in RCTs, but also in observational trials, included rate of complete healing of ulcers or post-operative wounds, healing time, reduction in area and number of amputations. Additionally, the studies reported on safety, and some featured cost-effectiveness analyses. The first individual RCT involving NPWT in DFS was published in 2005 and was conducted in 18 centres in the United States. 25 The researchers recruited 162 patients with partial foot amputation wounds, that is post-surgical, up to the transmetatarsal level and treated them with NPWT for 16 weeks. Of note, more patients experienced complete healing in the NPWT group than in the control group (56% vs 39%, respectively). Additionally, the rate of wound healing was faster in the NPWT group. This study was followed by the largest so far NPWT RCT in diabetes, involving almost 350 patients with chronic DFU. 26 This second study also showed a superiority of NPWT over the standard care with a 43.2% vs 28.9% healing rate, respectively. When these studies were summarized with others identified by two systematic reviews, two meta-analyses showed a superiority of NPWT in terms of efficacy outcomes without a rise in the incidence of adverse events. Data supporting its improved cost-effectiveness were also provided.
NPWT Mechanisms

Types of research
In modern-day medicine, it is important to confirm the results of RCTs with real-world evidence originating in everyday practice. This kind of data, while characterized by the obvious shortcomings related mainly to the nonrandom assignment of patients, comes from larger groups of patients and includes more possible outcomes. We have recently performed a systematic review and meta-analysis of observational, nonRCT studies examining NPWT in DFS with wounds (MTM, SB, JH unpublished data, manuscript under preparation). The largest contributing study was based on claims data from United States Medicare. 61 The analysis included 1135 patients with DFU treated with NPWT, with patients treated with wet-to-moist therapy from a published meta-analysis of RCTs used as controls. Again, a greater proportion of ulcers treated with NPWT achieved healing than in the comparator treatment group-46.3% vs 32.8% at 20 weeks. Our results based on the meta-analysis of this American paper and about a dozen of other nonrandomized studies, including our local Krakow observational data, 62 showed an advantage of NPWT therapy in one important outcome-major amputation rate. While the clinical data, both RCT and nonRCT in nature, seem to constitute a solid base for NPWT use in DFU, it is important to review its place in the diabetes clinical practice guidelines. The largest general diabetes guidelines published annually by the American Diabetes Association do not mention specifically NPWT therapy. 63 However, NWPT has been adopted as a treatment modality into guidelines specifically addressing wound healing or DFS. The European Wound Management Association (EWMA) has recently published an extensive summary on the use of NPWT in different clinical situations, including diabetes. 16 It is noteworthy that both important trials, by
Amstrong and Blume, were criticized by EWMA for their possible biases. 25, 26 In the first study, the option of directing study participants to surgery was up to the investigators. In the other trial, a high dropout rate was recorded. Nevertheless, EWMA concluded that NPWT is an important adjuvant therapy in the management of DFUs, and that one may expect its increasing use in this field. They emphasized that possible ischaemia and infection must be addressed before applying NPWT. European Wound Management Association also pointed to a technical progress in NPWT devices development over recent years. A more careful position was expressed by The International Working Group on the Diabetic Foot. 64 They separately considered post-surgical wounds and nonsurgical ulcers. The evidence for better efficacy as compared to the standard was identified to be more robust for the first type of wounds. Unlike the EWMA, the IWGDF thus hesitated to issue an unequivocal recommendation on the use of NPWT for nonsurgical wounds in light of the currently existing evidence. Both EWMA and IWGDF statements point to some possible NPWT adverse effects including skin damage, bleeding, infection, retention of dressings, as well as a failure to respond to NPWT device alarms and underline the need for appropriate staff training and organization.
| CONCLUSION
As highlighted above, diabetes and its complications will constitute a leading and rising challenge for global medicine in XXI century. One of the important elements of this complex diabetes picture is the subset of patients with DFS, the proportion of which is growing. Establishing an optimal model of diabetic foot care, including the use of modern technologies, will improve prognosis in this large cohort of patients. Here, we performed an extensive review of the basic and clinical research data related to NPWT, starting from the mechanisms of correction of pathophysiological abnormalities through clinical data and the place of negative pressure treatment in the clinical guidelines. This knowledge not only improves our understanding of NPWT action and tailoring of patients for its application, but may also allow the development of completely new medications and technologies for potential use in patients with DFS-related wounds in the near future.
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